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Abstract
Multimodal treatment approaches have substantially improved the outcome of breast cancer patients in the last
decades. Radiotherapy is an integral component of multimodal treatment concepts used in curative and palliative
intention in numerous clinical situations from precursor lesions such as ductal carcinoma in situ (DCIS) to advanced
breast cancer. This review addresses current controversial topics in radiotherapy with special consideration of DCIS,
accelerated partial breast irradiation (APBI) and regional nodal irradiation (RNI) and provides an update on the
clinical practice guidelines of the Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO).
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Background
Since 2005, the breast cancer expert panel of the
German Society for Radiation Oncology (DEGRO)
has published and updated evidence-based practical
guidelines for the treatment of breast cancer using
radiotherapy for the most important clinical situa-
tions [1–6].
Interdisciplinary efforts to pursue risk-adapted treat-
ment strategies have improved outcome for breast
cancer patients in the last decade. Subsequently, several
long-standing paradigms regarding the role of different
modalities have been scrutinized.
The most striking example for such a controversy in
the radiation oncology community was the introduction
of accelerated partial breast irradiation (APBI) for inva-
sive breast cancer, especially intraoperative radiotherapy
and the results of the TARGIT A-trial [7, 8]. Another
issue of dispute is the role of regional nodal irradiation
(RNI) in early stage breast cancer recently highlighted by
several randomized studies [9, 10]. Contrary to the re-
sults of trials which led to the established role of sentinel
lymph-node biopsy, these trials consistently showed a
benefit of intensified locoregional treatment, i.e. radio-
therapy to the regional lymphatic pathways.
Last but not least, debate continues about the optimal
risk-adapted treatment of ductal carcinoma in situ
(DCIS). Substantial effort has been dedicated to the
establishment of prognostic factors justifying the omis-
sion of adjuvant radiotherapy after breast-conserving
surgery. Furthermore, some researchers suggest a change
in the attitude towards low grade DCIS arguing that it
should be regarded as a risk factor for a subsequent
breast cancer rather than a malignant disease by itself.
The goal of this article is to provide an update on the
DEGRO practical guidelines for APBI, RNI and DCIS
with respect to recent data from randomised studies and
to discuss their possible impact on future developments.
Accelerated partial breast irradiation (APBI)
Mostly in order to shorten duration of treatment, APBI
is carried out with a variety of techniques for RT deliv-
ery. Its feasibility has been proven in randomized con-
trolled trials (RCT) for “anticipated” or postoperative
boost radiotherapy in addition to external beam whole
breast irradiation (WBI) [11].
Moreover, APBI has been administered as sole RT
modality applying different dose and fractionation
schemes using various target volume definitions [12].
Summarizing results of these trials, equieffectiveness of
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the various techniques is unclear and the differences in
patient characteristics as well as dosimetric characteris-
tics render the optimal selection of the treatment regi-
men as well as technique for individual patients difficult.
Table 1 summarizes the results and patient character-
istics of the recent randomized controlled trials of ABPI
versus WBI followed by a boost to the tumor bed.
Multicatheter brachytherapy
Multicatheter brachytherapy is the technique with the
longest experience for APBI and the only technique for
which 10 year-data from a randomized controlled trial
are available [13]. The Budapest trial did show similar
results with APBI using multicatheter brachytherapy and
WBI with a tumor bed boost, however this mono-
institutional trial was closed early due to poor enroll-
ment and the study was hence not adequately powered
to show non-inferiority of APBI [13].
Results from the randomized phase III noninferiority-
trial on interstitial multicatheter brachytherapy con-
ducted by the GEC-ESTRO group have been published
recently [14]. Between 2004 and 2009, 1184 patients
were randomized to APBI with with multicatheter
brachytherapy or percutaneous WBI of 50 Gy in 2 Gy
fractions with a sequential boost of 10 Gy. The primary
endpoint was ipsilateral local recurrence. The non-
inferiority-margin was set at a difference of 3% at 5 years.
At the time of analysis 14 patients had developed a local
recurrence at the 5 year-follow up. This corresponded to
a 5-year local recurrence rate of 0.9% for EBRT and 1.4%
for APBI as sole RT modality (p = 0.42). Overall survival
was 95.6% for EBRT and 97.3% for APBI (p = 0.11). Ad-
verse events occurred less frequently in the APBI-arm,
however statistical significance was only reached for
breast pain, which occurred in 3.2% after EBRT and 1.1%
after APBI (p = 0.04). Detailed results on late effects and
cosmetic outcome were not yet reported.
Intraoperative radiotherapy (IORT)
The TARGIT A-trial tested the approach of intraopera-
tive radiotherapy to the lumpectomy cavity using a
50 kV-device with a spherical applicator [15, 16].
Patients were randomized to WBI with or without a
tumor bed boost according to local standards or to
IORT with a dose of 20 Gy. However, additional WBI
was mandated in the case of additional risk factors iden-
tified in the pathologic work-up of the surgical specimen
which was the case for about 15% of patients in the
IORT-arm. TARGIT A was planned as a non-inferiority-
trial with a margin of 2.5% at 5 years. After the first
results were published in 2010 with the planned trial
cohort size of 2232 patients, recruitment was continued
until 2012 with a total size of 3451 patients. The trial
protocol was amended in 2004 to allow inclusion of
patients in which IORT was administered during a
second surgical procedure by reopening the wound
(post-pathology-stratum).
The most recent results were published in 2014 with a
median follow up of 29 months [15]. 1222 of the
patients included in this analysis had a median follow up
of 5 years. Results showed an estimated 5-year local
recurrence rate of 3.3% with IORT and 1.3% with WBI
(p = 0.043). This difference was not statistically signifi-
cant due to adjustment for multiple testing. Further-
more, non-inferiority was established for the whole
cohort, but not for the post-pathology stratum which
showed a 5-year local recurrence rate of 5.4% with IORT
and 1.7% with WBI (p = 0.067). The 5-year non-breast
cancer-related mortality was higher in the WBI-group
(3.5% vs. 1.4%, p = 0.089). A recently published report
provided further details on subgroup analyses and other
endpoints [17]. Tumors without expression of the pro-
gesterone receptor had a significantly increased risk of
local recurrence in the overall cohort and in the IORT-
arm. A multivariate analysis showed that non-inferiority
could not be established in the absence of estrogen and/
or progesterone receptor expression. The risk of recur-
rence outside of the index quadrant or the axilla was not
elevated in patients in the IORT-arm as compared to
patients in the EBRT-arm.
The publication of this trial evoked an unprecedented
discussion around the results of this trial in the Lancet and
in the Red Journal with criticism circling mainly around
the short overall follow up and the statistical design [7].
The second randomized phase III-trial on intraopera-
tive radiotherapy was the ELIOT-study, a single-
institutional trial using electrons (IOERT) instead of KV-
x-rays [18]. From 2000 to 2007, 1307 patients were
enrolled at the European Institute of Oncology in Milan,
Italy. The study was designed as an equivalence trial as-
suming a 5-year local recurrence rate of 3% in the WBI
group with an accepted non-inferiority margin of 4.5%.
The 5-year ipsilateral breast tumor recurrence rate,
although within the prespecified equivalence margin,
was significantly higher in the IOERT-arm with 4.4%
compared to 0.4% in the WBI-arm (p < 0.001). The risk
of recurrence was not only elevated in other breast
quadrants but also within the index quadrant and
regional lymph nodes. There was no difference in distant
recurrence or survival. The ELIOT trial provided
detailed information about risk factors for local tumor
recurrence in the IOERT group. Pathologic tumor size,
grading, estrogen receptor status, Ki-67 and molecular
subtype were significant predictors of an increased local
recurrence rate. In the absence of adverse prognostic
factors, the local recurrence rate was 1.1% in patients
treated with IOERT. Adverse events occurred less fre-
quently with IOERT with the exception of fat necrosis.
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External-beam radiotherapy
Interim results from the phase III randomized RAPID-
trial suggested that APBI with 3D-conformal EBRT
might be associated with inferior cosmesis and an ele-
vated risk of grade 1–2 adverse events [19]. While an
interrelation with dosimetric parameters as well as the
fractionation scheme of 38.5 Gy in 10 fractions over one
week was suspected, a follow up-publication failed to
identify treatment-associated predictors of adverse
cosmesis in the APBI-group [20].
Livi et al. conducted a randomized phase III-trial
using intensity-modulated radiotherapy (IMRT) for
APBI at the University of Florence [21]. The trial was
designed to detect an 2%-increase in the local
recurrence-rate at 5 years from 3% in the standard
arm to 5% in the APBI arm. From 2005 to 2013, 520
women were enrolled and randomized to 50 Gy of
WBI followed by a boost of 10 Gy or to 30 Gy of
APBI in 6 fractions over 2 weeks delivered as IMRT.
The clinical target volume for APBI contained the
surgical clip as determined by at least 4 clips placed
during surgery and an additional margin of 1 cm.
The 5 year-local recurrence rate was 1.5% in patients
receiving APBI and 1.4% in patients receiving stand-
ard treatment (p = 0.86). Toxicity and cosmesis were
significantly in favor of the APBI-arm.
At the 10th European Breast Cancer Conference
held in Amsterdam in April 2016, preliminary results
from the IMPORT LOW-trial were presented [22].
This 3-arm randomized phase III trial compared
hypofractionated WBI (40.05 Gy in 15 fractions, arm
A) to hypofractionated WBI with a lower dose to the
breast tissue outside of the tumor bed (40.05 Gy to
the tumor bed delivered as a simultaneous integrated
boost, 36 Gy to the remaining breast tissue in 15
fractions, arm B) and APBI to the tumor bed
(40.05 Gy in 15 fractions, arm C). 2018 patients were
recruited. 5-year local recurrence rates were 1.1% for
arm A, 0.2% for arm B and 0.5% for arm C. Non-
inferiority was demonstrated for the experimental
arms B and C (pre-defined threshold 2.5%, one-sided
alpha 2.5%).
Conclusions of the DEGRO expert panel
 APBI is feasible and provides excellent results
regarding toxicity and local control in selected
low risk-patients.
 Although non-inferiority was established in the
TARGIT A- and ELIOT-trial, there are some
methodologic issues in the design of those trials
including the additional use of EBRT, different
timing in the IORT application and the choice
of the non-inferiority margin.
 APBI using EBRT should be applied with caution
until the results of phase III trials such as NSABP
B-39/RTOG 0413, RAPID and IMPORT LOW
are published.
 Multicatheter brachytherapy remains the only
modality for which 10-year data are available.
 A meta-analysis including 4.489 patients from
several of the above mentioned trials
demonstrated that overall mortality is not
increased with APBI [23].
 Long term follow up is needed to determine
the impact of APBI on survival, the risk of late
recurrences, adverse events as well as cosmetic
results.
Radiotherapy of the lymphatic pathways in early stage
breast cancer
Sentinel lymph node metastases
Sentinel lymph node biopsy (SLNB) has replaced axillary
lymph node dissection (ALND) as the standard of care
for surgical staging of the axilla in patients with clinically
unsuspicious lymph nodes [24].
Controversy exists regarding the optimal treatment of
alleged low risk patients with 1–2 positive sentinel
lymph nodes. The ACOSOG Z0011 trial [25, 26] ran-
domly assigned 891 patients with T1-2 breast cancer
with sentinel lymph node metastases after breast-
conserving surgery to ALND or no further axillary sur-
gery. All patients were supposed to undergo standard
tangential WBI without irradiation of the supra-/infra-
clavicular region (SCN). The trial was designed as a
non-inferiority trial but was closed early due to slow re-
cruitment and low event rates. Overall, 40% patients had
micrometastases and 27% of patients in the ALND-arm
had additional non-sentinel lymph node metastases. The
10-year results were recently presented at the 2016
ASCO annual meeting and published [27]. Regional
nodal recurrence rates were low at 0.5% and 1.5% in the
ALND- and SLNB-arms, respectively (p = 0.28). There
were no significant differences in disease-free or overall
survival. However, a retrospective analysis of the avail-
able radiation treatment records revealed that there was
a significant number of protocol violations regarding
radiotherapy [28]. 18.9% of the reviewed patients re-
ceived radiotherapy to the SCN and more than half of
the patients were treated using high tangents known to
be associated with a higher radiation dose exposure to
axillary lymph node levels I and II compared to conven-
tional tangential irradiation. Protocol violations were
equally distributed between the two treatment arms, but
it cannot be excluded that RNI contributed to the favor-
able outcome in the SLNB-arm [29, 30].
The AMAROS-trial [31] conducted by the EORTC
addressed a similar patient group as Z0011 (cT1-2 cN0
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with sentinel lymph node metastases), however patients
with mastectomy were also eligible. 1425 patients were
randomly assigned to ALND or radiotherapy to axillary
lymph node levels I-III and the SCN. As the event rate
was lower than expected, the non-inferiority test for the
primary endpoint, the axillary recurrence rate, was
underpowered. Yet, axillary recurrence rates at 5 years
were low at 0.4% and 1.2% without any differences in
disease-free and overall survival. Axillary morbidity was
significantly higher in the ALND-arm with lymphedema
rates being almost twice as high as in patients treated
without ALND.
Conclusions of the DEGRO expert panel
 There is no clear standard for the treatment of
patients with 1–2 sentinel lymph node metastases.
It remains uncertain in which patients ALND and
RNI including the axilla can safely be omitted.
 Since radiotherapy to the axilla and the SCN yields
similar regional recurrence rate and survival
compared to axillary dissection while the associated
morbidity is reduced, it should always be considered
when treatment of the axilla seems indicated.
Recent results on radiotherapy of the lymphatic pathways
Several trials on RNI in early stage breast cancer were
recently published [32]. Design and results of those trials
are summarized in Table 2.
Generally, two types of trials can be distinguished,
those comparing the addition of RNI including the SCN
and the internal mammary lymph nodes (IMN) to whole
breast or chest wall irradiation to either one alone or
those trials addressing treatment of the whole breast or
chest wall and the SCN with or without irradiation of
the IMN.
The MA.20-[10] and the EORTC 22922/10925-[9]
trials belong to the first category. Both trials enrolled
mostly patients with 0–3 involved lymph nodes. How-
ever, there were several notable differences in the inclu-
sion criteria. While the MA.20-trial only recruited
patients after breast-conserving surgery, 24% of patients
in the EORTC-trial had undergone mastectomy. Node
negative patients were included in both trials, however
the EORTC-trial defined medial/central tumor location
as a prerequisite for eligibility in these patients whereas
the MA.20-trial used a combination of tumor size, num-
ber of removed lymph nodes and other risk factors.
Hence, the MA.20-trial included only 10% node negative
patients while 44% of the study population in the
EORTC-trial did not have nodal involvement.
Furthermore, there were differences in the radiation
technique [3]. Both trials did show significant improve-
ments in locoregional control, distant-metastasis-free
survival and disease-free survival. Interestingly, the
improvement in distant metastasis-free survival
exceeded the improvement in locoregional control, sug-
gesting that RNI could prevent distant spread [3]. Con-
cerning the primary endpoint overall survival, the
EORTC-trial was of significance after adjustment for
stratification factors (hazard ratio (HR) 0.87, p = 0.0496)
whereas the MA.20-investigators concluded that there
was no significant improvement in overall survival.
While a meta-analysis of both trials [33, 34] showed a
significant improvement in overall survival (HR 0.88, p =
0.034), subgroup analyses did not yield consistent results
on which patient subgroup might benefit most from RNI.
In MA.20, the overall survival benefit was most pro-
nounced in estrogen receptor-negative patients (HR 0.69,
p = 0.05) whereas in the EORTC-trial, this was true for
patients who did receive both endocrine and chemother-
apy (HR 0.72). These discrepancies might be related to the
differences in inclusion criteria regarding type of surgery
and node-negative patients (see Table 2).
The DBCG-IMN [35] and the French trial by
Hennequin et al. [36] belong to the second category of
clinical trials in RNI that specifically addressed the bene-
fit of targeting the IMN-area in RNI. The study of Hen-
nequin et al. [36] is the oldest one of the four mentioned
trials. It was designed to detect a 10% benefit in overall
survival in the patients treated with RNI including IMN
and was thus underpowered to show a difference be-
tween the two treatment arms. The DBCG-IMN trial
[35] is a prospective cohort study, but was meticiously
planned and executed. In patients with right sided breast
cancer, the internal mammary region was included into
the radiotherapy target volume, whereas in left sided
breast cancer patients this region was not treated due
to concerns regarding cardiac toxicity. The 8-year
overall survival rates were 75.9% with IMN-RT versus
72.2% without IMN-RT (HR 0.82, p = 0.005). Sub-
group analyses suggested that patients with 1–3 in-
volved lymph nodes in the case of medial/central
tumor location and patients with 4 or more involved
lymph nodes irrespective of the tumor location did
derive the largest benefit [35].
Conclusions of the DEGRO expert panel
 RNI improves the outcome of patients with early
stage breast cancer with locoregional lymph node
involvement.
 In patients with 1–3 involved lymph nodes, RNI
should be strongly considered, especially in the
presence of further risk factors such as negative
estrogen or progesterone receptor, poorly
differentiated tumors, medial tumor location and
premenopausal status.
Krug et al. Radiation Oncology  (2017) 12:25 Page 5 of 10
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 In patients with >3 involved lymph nodes, RNI
should be regarded as mandatory.
 Irradiation of the IMN should be strongly
considered in all patients in whom RNI is
performed.
 Currently, due to the differing inclusion criteria
for node negative patients in the MA.20- and the
EORTC-trials, the optimal selection criteria for
RNI in this subgroup remain unclear. However, it
can be discussed on a case by case-basis in patients
with the above-mentioned risk factors.
 Additional toxicity associated with RNI was mild
and none of the mentioned trials showed an increase
in cardiac morbidity or mortality, although further
follow-up is necessary regarding this endpoint.
Ductal carcinoma in situ (DCIS)
The effect of adjuvant radiotherapy on local recurrence
of DCIS after breast-conserving surgery has been estab-
lished by 4 randomized controlled phase III trials and a
meta-analysis of those trials by the Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG) [37].
Several recent publications have shed light on the
prognosis and treatment of patients with DCIS. Using
data from the Surveillance, Epidemiology and End
Results (SEER) registry, Narod et al. investigated the
prognosis of more than 108000 women with DCIS diag-
nosed between 1988 and 2011 [38]. The 20 year-breast
cancer-specific mortality was 3.3% overall, but increased
to 7.8% for women diagnosed before age 35 years. For
women with an ipsilateral invasive recurrence, the rela-
tive risk for dying of breast cancer was elevated 18-fold.
Radiotherapy did significantly reduce ipsilateral invasive
and non-invasive recurrences, but 10-year breast cancer-
specific mortality was similar with and without adjuvant
radiotherapy.
Another study from the SEER-registry by Sagara et al.
used the patient prognostic score developed by Smith et
al. [39] to assess the benefit of adjuvant radiotherapy ac-
cording to different clinical and pathologic factors [40].
Using the patient age (<40 years, 40–60 years, >60 years),
tumor size (<16 mm, 16–40 mm, > 40 mm) and grading
(low, intermediate, high), more than 32000 patients were
assigned a score from 0 to 6. The investigators used pro-
pensity score-corrections to account for imbalances in
baseline characteristics. Although breast cancer-specific
mortality was similar to the analysis by Narod et al. [38],
Sagara et al. could show a small but statistically signifi-
cant benefit in the 10 year breast cancer-specific mortal-
ity for patients who received adjuvant radiotherapy. The
benefit in terms of breast cancer-specific mortality and
overall mortality was highly dependent on the patient
prognostic score. Patients with higher scores derived the
largest benefit from radiotherapy with absolute
improvements in 10 year-breast cancer-specific mortality
of 1.9% and 4% in patients with a score of 4 and 5, re-
spectively. While these results suggest that it might be
possible to use the patient prognostic score to guide the
decision making-process for adjuvant radiotherapy, cau-
tion is advised because information on several important
factors such as margin status, endocrine therapy and co-
morbidities were lacking.
Due to the advances in diagnosis and treatment of
DCIS as well as declining rates of local recurrence [41],
the role of adjuvant radiotherapy has been questioned.
Several groups have tried to establish a definition of a
low risk-group of patients in which adjuvant radiother-
apy after breast-conserving surgery could safely be
omitted using clinical, pathological and molecular
parameters. However there is no consensus on which
factors should be used (for review see [42]).
The ECOG-ACRIN E5194-trial [43] prospectively
assessed the outcome of patients with DCIS after breast-
conserving surgery without adjuvant radiotherapy.
Patients were eligible if they had well or moderately dif-
ferentiated DCIS ≤ 2.5 cm (cohort 1) or poorly differenti-
ated DCIS ≤ 1 cm (cohort 2) with clear margins
(≥3 mm). Although median tumor size was only 6 mm
and 7 mm in the two cohorts with wide negative mar-
gins for most patients, the 12 year-local recurrence rates
were 14.4% and 24.6%, respectively. The 12 year-invasive
recurrence rates reached 7.5% and 13.4%, respectively.
The only randomized phase III trial specifically
studying the benefit of adjuvant radiotherapy in a
prospectively defined „low risk“ population is the
RTOG 9804-trial [44]. Women with well or moder-
ately differentiated DCIS with a tumor size of ≤
2.5 cm were randomly assigned to adjuvant WBI or
no radiotherapy after lumpectomy with clear margins.
The 7-year local recurrence rate was 0.9% with and
6.7% without adjuvant radiotherapy (p < 0.001, HR
0.11). 42% of local failures in the observation arm
were invasive recurrences. The rate of contralateral
invasive breast cancer (4% at 7 years) was consider-
ably lower than the rate of ipsilateral local failure
after radiotherapy, suggesting that radiotherapy could
prevent secondary tumors [45]. Toxicity associated
with radiotherapy was generally low.
There are several ongoing clinical trials addressing
active surveillance [46, 47] or chemoprevention (e.g.
CALGB 40903, ClinicalTrials.gov number, NCT01439711)
strategies in screening-detected biopsy-proven low or
intermediate DCIS. However, this is an experimental
approach and should not be chosen outside of clinical
trials [48]. A recent retrospective cohort study showed
that 20% of patients matching the inclusion criteria
for the LORIS-trial [47] after biopsy had invasive car-
cinoma on final pathology after surgery and 18% of
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those patients received a recommendation for adju-
vant chemotherapy [49].
A systematic review and meta-analysis by Nilsson et
al. [50] summarizes the current evidence on hypofractio-
nation and boost radiotherapy for DCIS. Results sug-
gested that moderately hypofractionated radiotherapy
(40–42 Gy in 15–16 fractions) is safe with a non-
significant trend towards an improvement in local
control compared to conventionally fractionated radio-
therapy (odds ratio 0.78, p = 0.08). There was a benefit
of a tumor bed boost in patients with positive margins
(odds ratio 0.56, p = 0.01). The evidence was mostly lim-
ited to small single-institutional retrospective studies
with a suboptimal quality of evidence.
A recent multicenter retrospective study presented at the
2016 annual meeting of the American Society for Radiation
Oncology included 4131 patients with DCIS [51].
Two thousand six hundred sixty-one patients received
a boost to the tumor bed with a median dose of 14 Gy.
Local control at 15 years was significantly better in
patients receiving a boost (91.6% vs. 88.0%, p = 0.013).
Patients with positive margins had no significant benefit,
however the subgroup was small with limited statistical
power.
Two randomized controlled trials, the TROG 07.01 trial
(NCT00470236) and the Bonbis trial (NCT00907868),
studying the role of a boost irradiation in patients with
DCIS have finished patient recruitment. The TROG 07.01
trial additionally addresses hypofractionation compared to
standard fractionation in a 2x2 trial design.
A discussion of adjuvant radiotherapy in patients with
DCIS should always include consideration of possible
late effects of radiotherapy. Cardiotoxicity of adjuvant
radiotherapy has been shown to be of relevance espe-
cially in patients with left-sided tumor location [52].
There is a clear dose–response relationship [53]. Thus,
modern radiotherapy techniques to reduce cardiac radi-
ation doses such as deep inspiration breath hold [54] are
of great importance to reduce long term morbidity.
Other possible severe late sequelae of radiotherapy in-
clude secondary malignancies. Although rare, the risk of
secondary malignancies is significantly elevated after
radiotherapy for breast cancer. This includes the risk for
subsequent lung cancer, esophageal cancer and sarcoma
[55]. Smokers should be counseled regarding their ele-
vated risk for both cardiac events and secondary lung
cancer after radiotherapy.
Conclusions of the DEGRO expert panel
 Clinical and pathological factors can help to
select patients at lower risk of local recurrence,
however there is no uniform definition of a low
risk-phenotype.
 Local recurrence rates show no plateau after
10 years of follow up in patients not undergoing
radiotherapy.
 Radiotherapy significantly lowers ipsilateral invasive
and non-invasive recurrences of DCIS after breast-
conserving surgery.
 Patients with high-risk DCIS derive the highest
absolute benefit from adjuvant radiotherapy.
 Although both invasive and non-invasive
recurrences are significantly reduced by
radiotherapy, there is no survival benefit.
 Patients should be informed about the beneficial
effects and low toxicity of radiotherapy with optimal
local control even in screening-detected DCIS.
 The rate of contralateral invasive breast cancer is
considerably lower than the rate of ipsilateral local
failure after radiotherapy, suggesting that
radiotherapy could prevent secondary tumors.
 The role of boost radiotherapy and hypofractionation
is currently unclear, however results from two
prospective randomized controlled trials are pending.
 In clinical practice, individual risk factors as well
as patient preferences, comorbidities and potential
side effects should be carefully weighed against
each other in the decision-making process concerning
adjuvant radiotherapy.
Conclusions and future challenges
The treatment of breast cancer is a poster child of
how multidisciplinary management can improve the
outcome of an oncologic disease. Using data from the
National Vital Statistics Reports and the SEER-
database, Smith et al. could show that from 1990 to
2007, the breast cancer death rate decreased about
2% per year [56]. The 10 year-breast cancer specific
death rate decreased from 29.6% to 20.1% for women
treated from 1980–1984 compared to women treated
from 1995–1997 (p < 0.001) [56].
With improving outcomes, better risk stratification
and patient selection for specific treatment ap-
proaches, the benefit achieved by individual treatment
modalities tends to decrease. Thus, an individual
treatment might provide a high relative benefit, but
with decreasing absolute benefit and increasing
number needed to treat, effects on morbidity and
non-breast cancer related mortality gain increasing
importance.
The basic goal to optimize treatment outcome may in-
volve different approaches and goals depending on the
specific risk-constellation of the disease. While in DCIS
and low risk-early stage breast cancer, it may be justified
to attempt de-escalation of treatment in order to limit
morbidity and preserve quality of life, the contrary i.e.
escalation of locoregional (radio-) therapy is indicated in
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node-positive breast cancer bearing a significant risk of
breast cancer-related mortality. Finding the optimal
combination of treatment approaches for achieving cure
while simultaneously balancing effectiveness against
morbidity requires individualization according to the in-
dividual risk, comorbidities and personal preferences of
the patient. These purposes are most likely achieved by
a multidisciplinary approach based on best available
evidence.
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